229 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
29
Perfluorinated hydroxamic acids are potent and selective inhibitors of HDAC-like enzymes from Pseudomonas aeruginosa.
University of Applied Sciences Darmstadt
12
Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors.
Broad Institute of Mit and Harvard
40
Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
West China Hospital of Sichuan University
4
Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.
University of Milan
8
Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
Sungkyunkwan University
24
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
Sichuan University
2
Orally available stilbene derivatives as potent HDAC inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts.
Orchid Chemicals & Pharmaceuticals
1
Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.
University of Minnesota
9
Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
Guangzhou Institute of Biomedicine and Health
11
Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators.
Shandong University
5
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
University of Minnesota
21
Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit.
University College London
11
Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
St. Jude Children'S Research Hospital
3
Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in sarcoma cancer stem cells.
Istituto Ortopedico Rizzoli (Ior)
21
Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.
TBA
16
Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.
Roche Pharmaceutical Research and Early Development
38
Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
Chinese Academy of Sciences
8
Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1/HDAC2 Inhibitor.
Merck Research Laboratories
4
Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
Taipei Medical University
36
Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold.
University of Siena
16
4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors.
University of Ferrara
11
Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
University of Milan
15
Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif.
Broad Institute of Mit and Harvard
5
Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
Heinrich Heine Universit£T
6
Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
Roche R & D Center China
15
Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth.
University of Illinois At Chicago
76
Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors.
Kyoto Prefectural University of Medicine
18
Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ¿F508-CFTR.
TBA
6
Effect of Inhibiting Histone Deacetylase with Short-Chain Carboxylic Acids and Their Hydroxamic Acid Analogs on Vertebrate Development and Neuronal Chromatin.
Broad Institute of Harvard and Mit
37
Optimization of a series of potent and selective ketone histone deacetylase inhibitors.
Irbm/Merck Research Laboratories
63
Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).
Merck Research Laboratories
33
A series of novel, potent, and selective histone deacetylase inhibitors.
Irbm/Merck Research Laboratories
15
Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand.
Institute of Technology
12
Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.
University of Illinois At Chicago
51
Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
S*Bio
27
A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold.
Broad Institute of Harvard and Mit
5
Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
Chroma Therapeutics
20
Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.
Universita` Degli Studi Di Siena
13
Non-Natural Macrocyclic Inhibitors of Histone Deacetylases: Design, Synthesis, and Activity
TBA
4
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
The Scripps Research Institute
37
Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
S*Bio
4
Synthesis and biological activity of cyclotetrapeptide analogues of the natural HDAC inhibitor FR235222.
University of Salerno
26
Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
Curis
2
Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
Ortho-Biotech Oncology Research & Development
16
Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors.
Methylgene
5
Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors.
Sigma-Tau Research and Development
16
Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
Irbm/Merck Research Laboratories
6
N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors.
R&D Sigma-Tau
22
Exploring the pharmacokinetic properties of phosphorus-containing selective HDAC 1 and 2 inhibitors (SHI-1:2).
Merck Research Laboratories
37
N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity.
S*Bio
32
SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103).
Methylgene
39
SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
Merck Research Laboratories
5
Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.
Institute of Organic Synthesis
29
The role of silicon in drug discovery: a review.
Pharmaceutical Technologies, Future Production: Chemicals, Council for Scientific and Industrial Research (CSIR)
5
Bifunctionality and Antitumor Efficacy of ZG-126, a Vitamin D Receptor Agonist/Histone Deacetylase Inhibitor Hybrid Molecule.
McGill University
37
Development of Hydrazide-Based HDAC6 Selective Inhibitors for Treating NLRP3 Inflammasome-Related Diseases.
Ocean University of China
38
Discovery of Novel 5-Cyano-3-phenylindole-Based LSD1/HDAC Dual Inhibitors for Colorectal Cancer Treatment.
Xinxiang Medical University
24
Discovery of the First-in-Class Dual-Target ROCK/HDAC Inhibitor with Potent Antitumor Efficacy in Vivo That Trigger Antitumor Immunity.
Zhejiang University
9
Simultaneous inhibition of FLT3 and HDAC by novel 6-ethylpyrazine-2-Carboxamide derivatives provides therapeutic advantages in acute myelocytic leukemia.
Shandong University
17
Design and Synthesis of Topoisomerases-Histone Deacetylase Dual Targeted Quinoline-Bridged Hydroxamates as Anticancer Agents.
Central University of Punjab
48
An Amazing 30-Year Journey around the DABO Family: A Medicinal Chemistry Lesson on a Versatile Class of Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors.
Sapienza University of Rome
13
Overview of the epigenetic/cytotoxic dual-target inhibitors for cancer therapy.
Gannan Medical University
3
Discovery of Highly Potent and Orally Bioavailable Histone Deacetylase 3 Inhibitors as Immunomodulators and Enhancers of DNA-Damage Response in Cancer Therapy.
Gannan Medical University
33
Indolo[3,2-c]isoquinoline Hydroxamic Acid Derivatives as Novel Orally Topoisomerase-Histone Deacetylase Dual Inhibitors for NSCLC Therapy.
China Pharmaceutical University
31
Discovery of N-Phenyl-5-propyl-1H-pyrazole-3-carboxamide, with Selective Inhibition and Degradation of HDAC6 for the Treatment of Acute Liver Injury.
Anhui Medical University
21
Seven-membered N-heterocycles as approved drugs and promising leads in medicinal chemistry as well as the metal-free domino access to their scaffolds.
Adam Mickiewicz University
21
Discovery of benzamide-based PI3K/HDAC dual inhibitors with marked pro-apoptosis activity in lymphoma cells.
Ocean University of China
33
Design and synthesis of 1H-benzo[d]imidazole selective HDAC6 inhibitors with potential therapy for multiple myeloma.
Sichuan University
14
Design, synthesis, and biological evaluation of novel HDAC/CD13 dual inhibitors for the treatment of cancer.
Ocean University of China
17
Tetrahydro-β-carboline derivatives as potent histone deacetylase 6 inhibitors with broad-spectrum antiproliferative activity.
Northwest A&F University
32
Discovery of potent pyrrolo-pyrimidine and purine HDAC inhibitors for the treatment of advanced prostate cancer.
University of Modena and Reggio Emilia
14
Advances in dual-targeting inhibitors of HDAC6 for cancer treatment.
Guizhou Medical University
36
Development of a First-in-Class DNMT1/HDAC Inhibitor with Improved Therapeutic Potential and Potentiated Antitumor Immunity.
Shandong University
21
Design, synthesis, and biological activity evaluation of novel HDAC3 selective inhibitors for combination with Venetoclax against acute myeloid leukemia.
Ocean University of China
21
Discovery of a Novel Benzimidazole Derivative Targeting Histone Deacetylase to Induce Ferroptosis and Trigger Immunogenic Cell Death.
Shandong University
21
Targeting Relevant HDACs to Support the Survival of Cone Photoreceptors in Inherited Retinal Diseases: Identification of a Potent Pharmacological Tool with In Vitro and In Vivo Efficacy.
University of Siena
20
Multimechanism biological profiling of tetrahydro-β-carboline analogues as selective HDAC6 inhibitors for the treatment of Alzheimer's disease.
Northwest A&F University
14
Re-exploration of tetrahydro-β-carboline scaffold: Discovery of selective histone deacetylase 6 inhibitors with neurite outgrowth-promoting and neuroprotective activities.
Yangling Vocational & Technical College
19
Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
Merck Research Laboratories
5
Synergistic therapeutics: Co-targeting histone deacetylases and ribonucleotide reductase for enhanced cancer treatment.
Manipal Academy of Higher Education
4
Multitargeting HDAC Inhibitors Containing a RAS/RAF Protein Interfering Unit.
Southeast University
13
5-(Trifluoromethyl)-1,2,4-oxadiazole (TFMO)-based highly selective class IIa HDAC inhibitors exhibit synergistic anticancer activity in combination with bortezomib.
Heinrich Heine University Dusseldorf
9
Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment.
Guru Ghasidas University
32
Development of a tetrahydroindazolone-based HDAC6 inhibitor with in-vivo anti-arthritic activity.
Sungkyunkwan University
13
Design, synthesis, and biological evaluation of HDAC6 inhibitors targeting L1 loop and serine 531 residue.
Keimyung University
32
Dual-targeting compounds possessing enhanced anticancer activity via microtubule disruption and histone deacetylase inhibition.
National Taiwan University
34
Discovery of novel itaconimide-based derivatives as potent HDAC inhibitors for the efficient treatment of prostate cancer.
China Pharmaceutical University
26
HDAC/NAMPT dual inhibitors overcome initial drug-resistance in p53-null leukemia cells.
Ocean University of China
11
Exploration of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on the Moiety of Fedratinib for Treatment of Both Hematologic Malignancies and Solid Cancers.
China Pharmaceutical University
63
Design and Synthesis of Triazole-Containing HDAC Inhibitors That Induce Antitumor Effects and Immune Response.
Xuzhou Medical University
9
Discovery of YSR734: A Covalent HDAC Inhibitor with Cellular Activity in Acute Myeloid Leukemia and Duchenne Muscular Dystrophy.
University of Toronto Mississauga
16
Development and Pharmacochemical Characterization Discover a Novel Brain-Permeable HDAC11-Selective Inhibitor with Therapeutic Potential by Regulating Neuroinflammation in Mice.
Sichuan University
4
Selective and Bioavailable HDAC6 2-(Difluoromethyl)-1,3,4-oxadiazole Substrate Inhibitors and Modeling of Their Bioactivation Mechanism.
AstraZeneca
3
Selective HDAC3 Inhibitors with Potent In Vivo Antitumor Efficacy against Triple-Negative Breast Cancer.
Birla Institute of Technology and Science-Pilani Hyderabad
58
The Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs.
Ghent University
25
Novel pyridine-containing histone deacetylase inhibitors strongly arrest proliferation, induce apoptosis and modulate miRNAs in cancer cells.
Sapienza University of Rome
25
Discovery of HDAC6, HDAC8, and 6/8 Inhibitors and Development of Cell-Based Drug Screening Models for the Treatment of TGF-β-Induced Idiopathic Pulmonary Fibrosis.
National Taiwan University
7
Discovery of the First Irreversible HDAC6 Isoform Selective Inhibitor with Potent Anti-Multiple Myeloma Activity.
Shandong University
36
Discovery of novel and bioavailable histone deacetylases and cyclin-dependent kinases dual inhibitor to impair the stemness of leukemia cells.
Nankai University
14
Histone deacetylases (HDACs) as the promising immunotherapeutic targets for hematologic cancer treatment.
Zhengzhou University
46
Synthesis and anticancer activity of novel histone deacetylase inhibitors that inhibit autophagy and induce apoptosis.
Wuyi University
11
Design, synthesis, and anti-inflammatory activity characterization of novel brain-permeable HDAC6 inhibitors.
Chinese Academy of Sciences
52
Discovery of novel, potent, and orally bioavailable HDACs inhibitors with LSD1 inhibitory activity for the treatment of solid tumors.
Xinxiang Medical University
21
Improved Selective Class I HDAC and Novel Selective HDAC3 Inhibitors: Beyond Hydroxamic Acids and Benzamides.
IRBM Science Park
10
Discovery of indole-piperazine derivatives as selective histone deacetylase 6 inhibitors with neurite outgrowth-promoting activities and neuroprotective activities.
Northwest A&F University
18
Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: Rational design, synthesis and antiproliferative activity.
Northwest A&F University
38
Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors.
Scripps Research
68
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
Menoufia University
19
Design, synthesis, biochemical evaluation, radiolabeling and in vivo imaging with high affinity class-IIa histone deacetylase inhibitor for molecular imaging and targeted therapy.
Stony Brook University
9
Histone deacetylase 6 inhibitors with blood-brain barrier penetration as a potential strategy for CNS-Disorders therapy.
Shanghai Institute of Pharmaceutical Industry
17
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
University of Toronto Mississauga
10
Developing HDAC4-Selective Protein Degraders To Investigate the Role of HDAC4 in Huntington's Disease Pathology.
Charles River Laboratories
3
Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
Ocean University of China
25
Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
Shandong University
38
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation.
Ocean University of China
3
Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier.
Taipei Medical University
5
Selective inhibition of histone deacetylase 3 by novel hydrazide based small molecules as therapeutic intervention for the treatment of cancer.
Birla Institute of Technology and Science-Pilani Hyderabad Campus
34
Paradigm shift of "classical" HDAC inhibitors to "hybrid" HDAC inhibitors in therapeutic interventions.
National Institute of Pharmaceutical Education and Research (NIPER)
31
Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies.
China Pharmaceutical University
3
Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent.
Taipei Medical University
24
From natural products to HDAC inhibitors: An overview of drug discovery and design strategy.
Chengdu University of Traditional Chinese Medicine
5
Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders.
Nirma University
17
A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
Zhengzhou University
4
Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer.
Guizhou Medical University
25
Potent Hydrazide-Based HDAC Inhibitors with a Superior Pharmacokinetic Profile for Efficient Treatment of Acute Myeloid Leukemia In Vivo.
Ocean University of China
21
Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype.
University of Toronto Mississauga
29
Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
Xinxiang Medical University
43
Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A
Shanghaitech University
4
Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).
China Pharmaceutical University
8
Discovery of a Series of Hydroxamic Acid-Based Microtubule Destabilizing Agents with Potent Antitumor Activity.
West China Hospital of Sichuan University
5
Indirubin Derivatives as Dual Inhibitors Targeting Cyclin-Dependent Kinase and Histone Deacetylase for Treating Cancer.
Guizhou Medical University
42
Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
Shandong University
6
Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency.
Children'S Hospital Affiliated To Zhengzhou University
20
Role of Fluorination in the Histone Deacetylase 6 (HDAC6) Selectivity of Benzohydroxamate-Based Inhibitors.
Italfarmaco
31
Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.
University of Illinois At Chicago
7
Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
University of Sharjah
2
Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
Nankai University
37
Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer.
Shenzhen Technology University
28
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
University of East Anglia
10
Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors.
Taipei Medical University
23
HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates.
The University of Queensland
32
Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2-Substituted Benzamide Zinc Binding Group.
Merck
10
Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models.
The George Washington University
27
Novel dual LSD1/HDAC6 inhibitors for the treatment of multiple myeloma.
Jubilant Therapeutics India
26
PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
University of Toronto Mississauga
42
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
A*Star
20
Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington's Disease.
Charles River Discovery
15
Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease.
Taipei Medical University
20
Recent advances in the discovery of potent and selective HDAC6 inhibitors.
Shandong University
3
Discovery of Potent Small-Molecule SIRT6 Activators: Structure-Activity Relationship and Anti-Pancreatic Ductal Adenocarcinoma Activity.
Sichuan University
19
Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for Clearance.
Merck
13
Discovery of 5-(4-methylpiperazin-1-yl)-2-nitroaniline derivatives as a new class of SIRT6 inhibitors.
Sichuan University
28
Characterization of Conformationally Constrained Benzanilide Scaffolds for Potent and Selective HDAC8 Targeting.
University of Toronto Mississauga
6
Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.
Sapienza University of Rome
13
Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment.
Taipei Medical University
43
Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.
University of Connecticut
22
Isoalantolactone/hydroxamic acid hybrids as potent dual STAT3/HDAC inhibitors and self-assembled nanoparticles for cancer therapy.
Wuyi University
107
HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.
Indian Csir-Central Drug Research Institute
5
Discovery of Novel Dual Histone Deacetylase and Mammalian Target of Rapamycin Target Inhibitors as a Promising Strategy for Cancer Therapy.
TBA
45
Synthesis and structure activity relationship of 1, 3-benzo-thiazine-2-thiones as selective HDAC8 inhibitors.
University of Applied Sciences
39
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
National Center For Advancing Translational Sciences
8
Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.
Umr Cnrs 7285
17
Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
University of Toronto Mississauga
17
N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression.
Taipei Medical University
3
Recent advances in class IIa histone deacetylases research.
Heinrich-Heine-Universit£T D£Sseldorf
2
Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
Sichuan University and Collaborative Innovation Center of Biotherapy
17
Synthesis and in Vitro and in Vivo Biological Evaluation of Tissue-Specific Bisthiazole Histone Deacetylase (HDAC) Inhibitors.
Chinese Academy of Sciences
28
Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models.
University of Illinois At Chicago
26
Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.
Ocean University of China
42
Discovery of Thieno[2,3-
Sichuan University and Collaborative Innovation Center of Biotherapy
4
Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.
Qingdao University
2
Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.
Institute of Biotechnology of The Czech Academy of Sciences
20
Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor.
Charles River Discovery (Previously Biofocus)
17
Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
Shandong University
15
Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors.
University of Connecticut
38
Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma.
Nestle Skin Health
36
Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
University of Navarra
5
Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
Taipei Medical University
10
Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
Xinxiang Medical University
22
Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11.
Forma Therapeutics
2
Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.
Csir-Indian Institute of Integrative Medicine
24
Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.
University of Regensburg
10
3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
Taipei Medical University
10
Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD).
University of Reims Champagne
17
Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors.
Ghent University
15
Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
National University of Singapore
19
Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.
Novartis Institutes For Biomedical Research
27
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
Taipei Medical University
12
Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status.
Medical University of South Carolina
17
Antimitotic amides for the treatment of cancer and proliferative disorders
Frost Biologic
59
Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof
Nurix Therapeutics
52
Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
Nikang Therapeutics
5
The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.
Fred Hutchinson Cancer Research Center
223
Compounds inhibiting leucine-rich repeat kinase enzyme activity
Merck Sharp & Dohme
6
Small-molecule factor D inhibitors targeting the alternative complement pathway.
Novartis Pharma
24
1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND USES THEREOF
Chong Kun Dang Pharmaceutical
45
Solution phase parallel synthesis of substituted 3-phenylsulfonyl-[1,2,3]triazolo[1,5-a]quinazolines: selective serotonin 5-HT(6) receptor antagonists.
Chemical Diversity Research Institute
3
COMPOUND INCLUDING 2,4-DIAMINOPYRIDINE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER
Korea Research Institute of Chemical Technology
7
Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity.
F. Hoffmann-La Roche
4
Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist.
Yamanouchi Pharmaceutical
15
Discovery of a novel member of the histamine receptor family.
The Centre For Addiction and Mental Health
5
Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1.
Torrey Pines Institute For Molecular Studies